OBJECTIVE: To investigate the application of β-lactam antibiotics/β-lactamase inhibitor compound preparations in Nanjing

so as to provide reference for rational drug use. METHODS: The consumption sum

daily defined dose system（DDDs） and other data of β-lactam antibiotics/β-lactamase inhibitor compound preparations in 67 hospitals in Nanjing from 2017 to 2020 were analyzed statistically. RESULTS: From 2017 to 2020

in terms of β-lactam antibiotics/β-lactamase inhibitor compound preparations in Nanjing

the drug with the highest consumption sum was cefoperazone sulbactam（2∶1）

and the top 2 drugs ranked by DDDs were amoxicillin clavulanate（7∶1） and amoxicillin clavulanate（4∶1）. Consumption sum and DDDs of the compound preparations containing sulbactam increased year by year

and the overall proportion was also high. Avibactam

a new β-lactamase inhibitor

was not used in China in 2017 and 2018. Since 2019

the consumption sum proportion and DDDs proportion of ceftazidime avitabtam were both at the lower level. Although the price of the drug was higher

however

its consumption sum and DDDs still showed a significant increase trend. Clinical non-mainstream varieties such as cefotaxime sulbactam（2∶1）

ceftriaxone sulbactam（2∶1） and mezlocillin sulbactam（4∶1） still occupied a certain amount. CONCLUSIONS: The clinical application of β-lactam antibiotics/β-lactamase inhibitor compound preparations in Nanjing basically follows the relevant guidelines

yet attention should be paid to the indications for the application of antibiotics and the selection of appropriate ratios of compound preparations during the application process

and the monitoring of rational clinical use of compound preparations containing β-lactamase inhibitors should be strengthened to promote the rational use of drugs and delay the bacterial resistance.